Revenue
2013
2014
2020
2021
2022
2023
2024
2025
Armata Pharmaceuticals, Inc. (ARMP)
Price—Loading quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $5.2M | $4.5M | $5.5M | $4.5M | $823,000 | — | — | — | — | — | $409,000 | $81,000 |
| Research & development | $23.7M | $34.4M | $33.8M | $35.0M | $20.0M | $14.4M | $9.8M | $8.4M | $2.9M | $5.7M | $4.0M | $5.8M | $6.5M |
| Operating expenses | $41.5M | $47.6M | $45.4M | $42.5M | $28.3M | $22.4M | $19.8M | $17.7M | $16.3M | $23.6M | $10.7M | $14.5M | $12.5M |
| Operating income | −$36.6M | −$42.4M | −$40.9M | −$36.9M | −$23.8M | −$21.6M | −$19.8M | −$17.7M | −$16.2M | −$23.4M | −$10.2M | −$14.1M | −$12.4M |
| Operating margin | −747.02% | −820.18% | −902.85% | −670.77% | −532.45% | −2,622.96% | — | — | — | — | — | −3,449.88% | −15,288.89% |
| EBITDA | −$35.1M | −$41.1M | −$39.9M | −$36.1M | −$22.7M | −$20.5M | −$18.4M | −$16.3M | −$15.8M | −$23.0M | −$9.9M | −$14.0M | −$12.3M |
| EBITDA margin | −715.80% | −794.57% | −881.39% | −654.58% | −506.33% | −2,487.61% | — | — | — | — | — | −3,411.25% | −15,149.38% |
| Net income | −$173.8M | −$18.9M | −$69.0M | −$36.9M | −$23.2M | −$22.2M | −$19.5M | −$16.7M | −$12.8M | −$18.8M | −$516,000 | $23.1M | −$64.6M |
| Net profit margin | −3,544.03% | −365.60% | −1,524.51% | −670.24% | −517.55% | −2,695.14% | — | — | — | — | — | 5,650.12% | −79,732.10% |
| Basic EPSper basic share | -$4.80 | -$0.52 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.49 | -$3.59 | -$28.15 | -$345.52 | -$27.87 | $58.96 | -$8.96 |
| Diluted EPSper diluted share | -$4.80 | -$0.89 | -$1.91 | -$1.08 | -$0.96 | -$1.35 | -$2.55 | -$3.59 | -$30.53 | -$345.52 | -$27.87 | -$32.63 | -$8.96 |
Owners
Reported shareholders
5.67%of listed shares
Madison Asset Management, LLC2.11M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Madison Asset Management, LLC | 5.67%2.11M shares |
BlackRock, Inc. | 1.51%559.99K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.31%487.97K shares |
MILLENNIUM MANAGEMENT LLC | 1.27%470.5K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.73%270.55K shares |
Birx Deborah | ≈0.57%212.46K shares |
Dauntless Investment Group, LLC | 0.55%203.89K shares |
STATE STREET CORP | 0.35%129.6K shares |
NORTHERN TRUST CORP | 0.24%89.79K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.22%81.35K shares |
EDGEWOOD MANAGEMENT LLC | 0.22%80K shares |
VANGUARD FIDUCIARY TRUST CO | 0.21%79.5K shares |
Grey Ledge Advisors, LLC | 0.13%50K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.13%48.32K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.12%44.68K shares |
SeaCrest Wealth Management, LLC | 0.11%41.52K shares |
Bank of New York Mellon Corp | 0.08%29.75K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.08%28.86K shares |
Hudson Bay Capital Management LP | 0.05%17.58K shares |
Nuveen, LLC | 0.04%15.91K shares |
Percentages use 37.15M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data